Author(s):
Akshay Gade, Rutuja Sawant, Shreya Parkar, Prajakta Kegade
Email(s):
gadeakshay97@gmail.com
DOI:
10.5958/2231-5713.2020.00044.6 
Address:
Mr. Akshay Gade*, Miss. Rutuja Sawant, Miss. Shreya Parkar, Miss. Prajakta Kegade
Department of Pharmaceutics, M Pharmacy, University of Mumbai, Vidya Nagari, Kalina, Santacruz East, Mumbai, Maharashtra 400098.
*Corresponding Author
Published In:
Volume - 10,
Issue - 4,
Year - 2020
ABSTRACT:
Polycystic Ovarian Syndrome (PCOS) is the major hormonal disorder in women mainly of reproductive age. PCOS is polygenic endrocine disorder characterized by chronic anovulation and excess ovarian activity the most common gynaecological endocrinopathy. PCOS is associated with low-grade chronic inflammation and that women with PCOS are at increased risk of non-alcoholic fatty liver disease. The diagnosis and treatment of PCOS are not complicated, it only requires appropriate therapeutic approaches addressing hyperandrogenism and the judicious application of a well-standardized diagnostic methods. Menstrual cycle alteration is the one of the diagnosis criteria of PCOD. With reactivation of the GnRH pulse generator, increased gonadotropin secretion stimulates ovarian estrogen secretion and follicular development. Estrogen promotes uterine growth and endometrial proliferation; endometrial estrogen exposure eventually culminates in vaginal withdrawal bleeding and menarche. Ultrasonography eval¬uation of ovarian morphology might not be required for diagnosis in women already presenting with clinical evidence of hyperandrogenism and ovulatory dysfunc¬tion. To prevent multiple births and OHSS in patients with PCOS several modifications to IVF have been proposed, elective cryopreservation of all embryos and transfer in a subsequent frozen embryo transfer cycle after ovarian recovery, including in vitro maturation (IVM) of immature oocytes that are retrieved without gonadotropin stimula¬tion.Treatment should be tailored to the need of the patient andinvolves, medication and potentially surgery for the prevention and management of excess weight,targeting metabolic abnormalities through lifestyle changes, androgen suppression and/or blockade, endometrial safety, reproductive therapy and the detection and treatment of psychological features.
Cite this article:
Akshay Gade, Rutuja Sawant, Shreya Parkar, Prajakta Kegade. Polycystic ovary syndrome: An Overview, Diagnosis and Treatment of PCOS. Asian J. Pharm. Tech. 2020; 10(4):265-272. doi: 10.5958/2231-5713.2020.00044.6
Cite(Electronic):
Akshay Gade, Rutuja Sawant, Shreya Parkar, Prajakta Kegade. Polycystic ovary syndrome: An Overview, Diagnosis and Treatment of PCOS. Asian J. Pharm. Tech. 2020; 10(4):265-272. doi: 10.5958/2231-5713.2020.00044.6 Available on: https://ajptonline.com/AbstractView.aspx?PID=2020-10-4-8
REFERENCE:
1. Azziz, R. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009).
2. Barry JA, Azizia MM, Hardiman PJ: Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–58. 10.1093/humupd/dmu012.
3. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest. 2006; 29:270–80.
4. Beydoun HA, Stadtmauer L, Beydoun MA, Russell H, Zhao Y, Oehninger S. Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies. Reprod Biomed Online. 2009; 18:856–63.
5. Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J ObstetGynecolReprod Biol. 2016; 207:214–9.
6. Stepto, N. K. et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic–hyperinsulaemic clamp. Hum. Reprod. 28, 777–784 (2013).
7. Rocca ML, Venturella R, Mocciaro R, Di Cello A, Sacchinelli A, Russo V, et al. Polycystic ovary syndrome: chemical pharmacotherapy. Expert OpinPharmacother. 2015; 16:1369–93.
8. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest. 2006; 29:270–80.
9. Beydoun HA, Stadtmauer L, Beydoun MA, Russell H, Zhao Y, Oehninger S. Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies. Reprod Biomed Online. 2009; 18:856–63.
10. Stepto, N. K. et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic–hyperinsulaemic clamp. Hum. Reprod. 28, 777–784 (2013).
11. Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J ObstetGynecolReprod Biol. 2016; 207:214–9.
12. Hickey M., Sloboda D. M., Atkinson H. C., Doherty D. A., Franks S., Norman R. J., et al. . (2009). The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J. Clin. Endocrinol. Metab. 94, 3714–3720. 10.1210/jc.2009-0544.
13. de Zegher F., Lopez-Bermejo A., Ibáñez L. (2009). Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol. Metab. 20, 418–423. 10.1016/j.tem.2009.06.003.
14. de Zegher F., Lopez-Bermejo A., Ibáñez L. (2009). Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol. Metab. 20, 418–423. 10.1016/j.tem.2009.06.003.
15. Azziz, R. PCOS in 2015: New insights into the genetics of polycystic ovary syndrome. Nat. Rev. Endocrinol.12, 74–75 (2016).
16. Berger, S. L., Kouzarides, T., Shiekhattar, R. andShilatifard, A. An operational definition of epigenetics. Genes Dev. 23, 781–783 (2009).
17. Pache TD, Fauser BC. Polycystic ovaries in female-to-male transsexuals. Clin Endocrinol (Oxf). 1993; 39(6):702–703.
18. Lehman MN, Coolen LM, Goodman RL. Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology. 2010; 151(8):3479–3489.
19. Azziz, R. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009).
20. Souter, I., Sanchez, L. A., Perez, M., Bartolucci, A. A. andAzziz, R. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am. J. Obstet. Gynecol. 191, 1914–1920 (2004).
21. Azziz R, carmina E, chen Z, et al. Polycystic ovary syndrome. .Nat Rev Dis primers, 2016; 2:16057.published 2016 Aug 11.
22. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015; 36(5):487–525.
23. Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M. and Raff, H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J. Clin. Endocrinol. Metab. 92, 405–413 (2007).
24. Rosner W, Vesper H; Endocrine Society; American Association for Clinical Chemistry; American Association of Clinical Endocrinologists; Androgen Excess/PCOS Society; American Society for Bone and Mineral Research; American Society for Reproductive Medicine; American Urological Association; Association of Public Health Laboratories; Endocrine Society; Laboratory Corporation of America; North American Menopause Society; Pediatric Endocrine Society. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab. 2010;95(10):4542–4548.
25. Centers for Disease Control and Prevention. HoSt testosterone certified procedures. CDC https://www. cdc.gov/labstandards/ pdf/hs/CDC_Certified_ Testosterone_Procedures.pdf (2017).
26. Azziz, R. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009).
27. Biro FM, Pajak A, Wolff MS, Pinney SM, Windham GC, Galvez MP, Greenspan LC, Kushi LH, Teitelbaum SL. Age of menarche in a longitudinal US cohort. J PediatrAdolesc Gynecol. 2018; 31(4):339–345.
28. Gunn HM, Tsai MC, McRae A, Steinbeck KS. Menstrual patterns in the first gynecological year: a systematic review. J PediatrAdolesc Gynecol. 2018; 31(6):557–565.e6.
29. Azziz, R. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009).
30. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, Escobar-Morreale HF. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014; 20(3):334–352.
31. Escobar-Morreale, H. F. Diagnosis and management of hirsutism. Ann. NY Acad. Sci. 1205, 166–174 (2010).
32. Yoo RY, Sirlin CB, Gottschalk M, Chang RJ. Ovarian imaging by magnetic resonance in obese adolescent girls with polycystic ovary syndrome: a pilot study. FertilSteril. 2005; 84:985–995.
33. Sahmay S, Aydin Y, Oncul M, Senturk LM. Diagnosis of polycystic ovary syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet. 2014; 31:213–20.
34. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Human Reproduction Update. 2008; 14:367–78.
35. Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013; 19:519–650.
36. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of Anti-Müllerian hormone in women. Hum Reprod Update. (2014) 20:370–85. 10.1093/humupd/dmt062.
37. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. . The physiology and clinical utility of Anti-Müllerian hormone in women. Hum Reprod Update. (2014) 20:370–85. 10.1093/humupd/dmt062.
38. Balen AH, Conway GS, Kaltsas G, Kitirak T, Manning PJ, West C, et al. Andrology: polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. (1995) 10:2107–11. 10.1093/oxfordjournals.humrep.a136243.
39. Legro RS, Arslanian SA, Ehrmann DA, et al.; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(12):4565–4592.
40. Brown ZA, Louwers YV, Fong SL, et al. : The phenotype of polycystic ovary syndrome ameliorates with aging. FertilSteril. 2011; 96(5):1259–65. 10.1016/j.fertnstert.2011.09.002.
41. Bellver J, Rodríguez-Tabernero L, Robles A, et al.: Polycystic ovary syndrome throughout a woman’s life. J Assist Reprod Genet. 2018; 35(1):25–39. 10.1007/s10815-017-1047-7.
42. Dewailly D, Pigny P, Soudan B, et al. . Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab.2010; 95:4399–4405.
43. Carmina E, Oberfield SE, Lobo RA.The diagnosis of polycystic ovary syndrome in adolescents Am J ObstetGynecol2010; 203:201–205.
44. Witchel SF, Oberfield S, Rosenfield RL, et al.: The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Horm Res Paediatr. 2015; 83:376–389. 10.1159/000375530.
45. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine clinical practice guideline. In: Program of the 95th Annual Meeting of The Endocrine Society; June 15–18, 2013; San Francisco, CA.
46. Teede HJ, Misso ML, Costello MF, et al.: Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–18. 10.1093/humrep/dey256.
47. Shah D, Bansal S: Polycystic ovaries - beyond menopause. Climacteric. 2014;17(2):109–15. 10.3109/13697137.2013.828687.
48. Conway, G. et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 171, 1–29 (2014).
49. Thomson, R. L. et al. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil. Steril. 94, 1812–1816 (2010).
50. Luque-Ramírez M, Nattero-Chávez L, Ortiz Flores AE, et al: Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018; 24: 225–41. 10.1093/ humupd/dmx039.
51. Escobar-Morreale, H. F. et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum. Reprod. Update 18, 146–170 (2012).
52. Misso M, Boyle J, Norman R, et al. Development of evidenced-based guidelines for PCOS and implications for community health. SeminReprod Med 2014; 32: 230–240.
53. Guidi J, Gambineri A, Zanotti L, et al. Psychological aspects of hyperandrogenic states in late adolescent and young women. Clin Endocrinol (Oxf) 2015; 83: 872–878.
54. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003; 14(8):365–370.
55. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002; 105(23):2696–2698.
56. Balfour, J. A. and McClellan, K. Topical eflornithine. Am. J. Clin. Dermatol. 2, 197–201; discussion 202 (2001).
57. Swiglo, B. A. et al. Clinical review: antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J. Clin. Endocrinol. Metab.93, 1153–1160 (2008).
58. Townsend, K. A. and Marlowe, K. F. Relative safety and efficacy of finasteride for treatment of hirsutism. Ann. Pharmacother. 38, 1070–1073 (2004).
59. Lizneva, D., Gavrilova Jordan, L., Walker, W. andAzziz, R. Androgen excess: investigations and management. Best Pract. Res. Clin. Obstet. Gynaecol. http://dx.doi.org/10.1016/ j.bpobgyn.2016.05.003 (2016).
60. Legro, R. S. et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 371, 119–129 (2014).
61. Sagle, M. A., Hamilton Fairley, D., Kiddy, D. S. and Franks, S. A comparative, randomized study of low dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome. Fertil. Steril. 55, 56–60 (1991).
62. Polson, D. W., Mason, H. D., Saldahna, M. B. and Franks, S. Ovulation of a single dominant follicle during treatment with low-dose pulsatile follicle stimulating hormone in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 26, 205–212 (1987).
63. Legro RS, Arslanian SA, Ehrmann DA, et al.; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592.
64. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;(1):CD005552.
65. Costello M., Shrestha B., Eden J., Sjoblom P., Johnson N. (2007). Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst. Rev. CD005552. 10.1002/ 14651858.CD005552.pub2.
66. Yildiz B. O. (2008a). Assessment, diagnosis and treatment of a patient with hirsutism. Nat. Clin. Pract. Endocrinol. Metab. 4, 294–300. 10.1038/ncpendmet0789.
67. Bayer LL, Hillard PJ. Use of levonorgestrel intrauterine system for medical indications in adolescents. J Adolesc Health. 2013;52(4 suppl): S54–S58.
68. Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78(8):782–785.
69. Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. FertilSteril 2009; 92: 1966–1982.
70. Donesky, B. W. andAdashi, E. Y. Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy. Fertil. Steril.63, 439–463 (1995).
71. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. FertilSteril. 2008; 89:505–22.
72. Amer SA. Laparoscopic ovarian surgery for polycystic ovarian syndrome. In: Dunlop W, Ledger WL, editors. Recent Advances in Obstetrics and Gynaecology. 24th ed. London: Royal Society of Medicine Press Ltd; 2009. pp. 227–43.
73. Api, M. Is ovarian reserve diminished after laparoscopic ovarian drilling? Gynecol. Endocrinol. 25, 159–165 (2009).
74. Nahuis, M. J. et al. Long-term outcomes in women with polycystic ovary syndrome initially randomized to receive laparoscopic electrocautery of the ovaries or ovulation induction with gonadotrophins. Hum. Reprod. 26, 1899–1904 (2011).
75. Zhu X, Ye H, Fu Y. The utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine (Baltimore) 2016; 95:e4193.
76. Cha, K. Y. et al. Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization–embryo transfer. Fertil. Steril.83, 1461–1465 (2005).
77. McHorney, C. A. Health status assessment methods for adults: past accomplishments and future challenges. Annu. Rev. Public Health 20, 309–335 (1999).
78. Colwell HH, Mathias SD, Pasta DJ, et al. A health -related quality of life instrument for symptomatic patients with endometriosis: a validation study. Am J ObstetGynecol 1998; 179:47–55.
79. The Amsterdam EA-SrPCWG. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012; 27:14–24.
80. Wang A, Mo T, Li Q, et al. The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. Endodrine 2019; 64:220–32.
81. Kite C, Lahart IM, Afzal I, et al. Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Syst Rev 2019; 8:51.
82. Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011.